KER-050

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
140 patients (estimated)
Sponsors
Keros Therapeutics, Inc.
Tags
Growth Factor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1646
NCT Identifier
NCT04419649

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.